Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Oxford Technology Management: Delivering Success from Seed Capital Investment




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Oxford Technology Management: Delivering Success from Seed Capital Investment
Released on: September 01, 2007. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this exclusive interview, Fintan Walton talks to Matthew Frohn, Director of Oxford Technology Management about seed capital investment in technology companies.
  • Summary
  • Transcript
  • Participants
  • Company
In this exclusive interview, Fintan Walton talks to Matthew Frohn, Director of Oxford Technology Management about seed capital investment in technology companies. Matthew begins by explaining Oxford Technology Management’s investment strategy to date and the sorts of companies in which he is looking to invest. They discuss the different timelines to commercialisation that affect new companies in different industry sectors, with IT companies more likely to generate revenues in the short-term than life science companies, thus supporting a diversified investment portfolio. The requirements to be successful and to get to the next round of financing are also considered, with Matthew explaining that he looks for milestones that need to be achieved in order to de-risk the technology.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Dr Matthew Frohn graduated from Oxford Brookes University with a degree in Cell and Molecular Biology followed by a DPhil in Biochemistry from Oxford University. He worked on research collaborations with AstraZeneca, and had a short research post with a British Biotech subsidiary before joining Oxford Technology Management in 1999, as the manager of the Oxford Technology VCTs. He is particularly involved with Oxford Technology Management’s life science investments.
Oxford Technology Management